HuGE Literature Finder
Records
1
-
11
| Polymorphisms in solute carrier genes (SLC19A1, SLCO1B1, and SLCO1B3) predicts survival and toxicity in North Indian lung cancer patients undergoing platinum-based doublet chemotherapy. Journal of clinical pharmacy and therapeutics 2022 Jul . Sharma Parul, Singh Navneet, Sharma Siddhar |
| Genetic polymorphism in ATIC is associated with effectiveness and toxicity of pemetrexed in non-small-cell lung cancer. Thorax 2021 Apr . Visser Sabine, Koolen Stijn, van Donk Nadine, van Walree Nico, van der Leest Cor, Cornelissen Robin, van Schaik Ron, Mathijssen Ron, Aerts Joachim, Stricker Bruno |
| Discovery of Novel Biomarkers of Therapeutic Responses in Han Chinese Pemetrexed-Based Treated Advanced NSCLC Patients. Frontiers in pharmacology 2019 10 944. Zhang Xiaoqing, Zhang Di, Huang Lihua, Li Guorong, Chen Luan, Ma Jingsong, Li Mo, Wei Muyun, Zhou Wei, Zhou Chenxi, Zhu Jinhang, Wang Zhanhui, Qin Shengyi |
| Folate/homocysteine metabolism and lung cancer risk among smokers. PloS one 2019 14 (4): e0214462. Stanislawska-Sachadyn Anna, Borzyszkowska Joanna, Krzeminski Michal, Janowicz Alicja, Dziadziuszko Rafal, Jassem Jacek, Rzyman Witold, Limon Janu |
| Impact of DNA repair, folate and glutathione gene polymorphisms on risk of non small cell lung cancer. Pathology, research and practice 2017 Nov . Pérez-Ramírez Cristina, Cañadas-Garre Marisa, Alnatsha Ahmed, Villar Eduardo, Delgado Juan Ramón, Calleja-Hernández Miguel Ángel, Faus-Dáder María Jo |
| Pharmacogenetics of pemetrexed combination therapy in lung cancer: pathway analysis reveals novel toxicity associations. The pharmacogenomics journal 2014 Oct 14 (5): 411-7. Corrigan A, Walker J L, Wickramasinghe S, Hernandez M A, Newhouse S J, Folarin A A, Lewis C M, Sanderson J D, Spicer J, Marinaki A |
| Polymorphisms in thymidylate synthase and reduced folate carrier (SLC19A1) genes predict survival outcome in advanced non-small cell lung cancer patients treated with pemetrexed-based chemotherapy. Oncology letters 2013 Apr 5 (4): 1165-1170. Li Wen-Juan, Jiang Hua, Fang Xin-Jian, Ye Hong-Ling, Liu Ming-Huan, Liu Yan-Wen, Chen Qian, Zhang Li, Zhang Jin-Yu, Yuan Chun-Luan, Zhang Qiu-Y |
| Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011 Dec . Smit EF, Socinski MA, Mullaney BP, Myrand SP, Scagliotti GV, Lorigan P, Reck M, Ciuleanu T, von Pawel J, Karaseva NA, Szczesna A, Ohannesian D, Powell E, Hozak RR, Hong S, Guba SC, Thatcher N |
| Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2010 Sep 5 (9): 1346-53. Adjei Araba A, Salavaggione Oreste E, Mandrekar Sumithra J, Dy Grace K, Ziegler Katie L Allen, Endo Chiaki, Molina Julian R, Schild Steven E, Adjei Alex |
| Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Feb 28 (4): 614-9. Adjei Alex A, Mandrekar Sumithra J, Dy Grace K, Molina Julian R, Adjei Araba A, Gandara David R, Ziegler Katie L Allen, Stella Philip J, Rowland Kendrith M, Schild Steven E, Zinner Ralph |
| Polymorphisms in folate metabolic genes and lung cancer risk in Xuan Wei, China. Lung cancer (Amsterdam, Netherlands) 2005 Sep 49 (3): 299-309. Shen Min, Rothman Nathaniel, Berndt Sonja I, He Xingzhou, Yeager Meredith, Welch Robert, Chanock Stephen, Caporaso Neil, Lan Qi |
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 22, 2023
- Content source: